Latent membrane protein 1 of Epstein-Barr virus: Signaling pathways and oncogenic properties;La protéine oncogène LMP1 du virus d'Epstein-Barr: Voies de signalisation et phénotypes associés

Virologie

Volumn 6, Issue 5, 2002, Pages 379-390

  Masy, E ^a   Adriaenssens, E ^a   Auriault, C ^a   Coll, Jean ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

EBV; LMP 1; Signaling pathways; Transformation

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; LATENT MEMBRANE PROTEIN 1; STAT PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS PROTEIN;

B LYMPHOCYTE; CARCINOGENESIS; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; EPSTEIN BARR VIRUS; HODGKIN DISEASE; LYMPHOBLASTOID CELL LINE; MACROPHAGE; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; ONCOGENE; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; TRANSGENIC MOUSE;

EID: 0036756243     PISSN: 12678694     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Kawa K. Epstein-Barr virus-associated diseases in humans. Int J Hematol 2000; 71: 108-17.
2. Thorley-Lawson DA. Epstein-Barr virus: Exploiting the immune system. Nature Rev Immunol 2001; 1: 75-82.
3. Pai S, Khanna R. Role of LMP1 in immune control of EBV infection. Semin Cancer Biol 2001; 11: 455-60.
4. Wang D, Liebowitz D and Kieff E. An Epstein-Barr virus membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985; 43: 831-40.
5. Liebowitz D, Kopan R, Fuchs E, Sample J, Kieff E. An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes. Mol Cell Biol 1987; 7: 2299-308.
6. Eliopoulos AG, Rickinson AB. Epstein-Barr virus: LMP1 masquerades as an active receptor. Curr Biol 1998; 8: R196-8.
7. Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs): A family of adapter proteins that regulates life and death. Genes Dev 1998; 12: 2821-30.
8. Eliopoulos AG, Young LS. LMP1 structure and signal transduction. Semin Cancer Biol 2001; 11: 435-44.
9. Devergne O, Hatzivassiliou E, Izumi KM, et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation role in NF-kappaB activation. Mol Cell Biol 1996; 16: 7098-108.
10. Izumi KM, Kaye KM, Kieff ED. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci USA 1997; 94: 1447-52.
11. Kieser A, Kaiser C, Hammerschmidt W. LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. Embo J 1999; 18: 2511-21.
12. Gires O, Kohlhuber F, Kilger E, et al. Latent membrane protein 1 of Epstein-Barr virus interact with JAK3 and activates STAT proteins. Embo J 1999; 18: 3064-73.
13. Higuchi M, Kieff E, Izumi KM. The Epstein-Barr virus latent membrane protein 1 putative Janus kinase 3 (JAK3) binding domain does not mediate JAK3 association or activation in B-lymphoma or lymphoblastoid cell lines. J Virol 2002; 76: 455-9.
14. Hong SY, Yoon WH, Park JH, Kang SG, Ahn JH, Lee TH. Involvement of two NF-kappa B binding elements in tumor necrosis factor alpha-, CD40-, and epstein-barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene. J Biol Chem 2000; 275: 18022-8.
15. Kenney JL, Guinness ME, Reiss M, Lacy J. Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) sensitizes EBV-immortalized B cells to transforming growth factor-beta and chemotherapeutic agents. Int J Cancer 2001; 91: 89-98.
16. Izumi KM. Identification of EBV transforming genes by recombinant EBV technology. Semin Cancer Biol 2001; 11: 407-14.
17. Groux H, Cottrez F, Montpellier C, et al. Isolation and characterization of transformed human T-cell lines infected by Epstein-Barr virus. Blood 1997; 89: 4521-30.
18. Masy E, Adriaenssens E, Montpellier C, et al. Human monocytic cell lines in vitro transformed by the Epstein-Barr virus display a type II latency and LMP-1 dependent proliferation. J Virol 2002; 76: 6460-72.
19. Kulwichit W, Edwards R, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998; 95: 11963-8.
20. Curran JA, Laferty FS, Campbell D, Macdiarmid J, Wilson JB. Epstein-Barr virus encoded latent membrane protein-1 induces epithelial cell proliferation and sensitizes transgenic mice to chemical carcinogenesis. Cancer Res 2001; 61: 6730-8.
21. Xin B, He Z, Yang X, Chan CP, Ng MH, Cao L. TRADD domain of Epstein-Barr virus transforming protein LMP1 is essential for inducing immortalization and suppressing senescence of primary rodent fibroblasts. J Virol 2001; 75: 3010-5.
22. Kawanishi M. Expression of Epstein-Barr virus latent membrane protein 1 protects Jurkat T-cell from apoptosis induced by serum deprivation. Virology 1997; 228: 244-50.
23. Montpellier C, Crépieux P, Quatannens B, et al. Homologous T and B cells immortalized in vitro by the Epstein-Barr virus exhibit differential genetical and functionnal features. Int J Oncol 1997; 11: 87-96.
24. Kim KR, Yoshizaki T, Miyamori H, et al. Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth. Oncogene 2000; 19: 1764-71.
25. Horikawa T, Sheen TS, Takeshita H, Sato H, Furukawa M, Yoshizaki T. Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol 2001; 159: 27-33.
26. Silverman N MT. NF-kappaB signaling pathways in mammalian and insect innate immunity. Genes Dev 2001; 15: 2321-42.
27. Luftig MA, Cahir-McFarland E, Mosialos G, Kieff E. Effects of the NIK aly mutation on NF-kappaB activation by the Epstein-Barr virus latent infection membrane protein, lymphotoxin beta receptor, and CD40. J Biol Chem 2001; 276: 14602-6.
28. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001; 412: 346-51.
29. Fries KL, Miller WE, Raab-Traub N. The A20 protein interacts with the Epstein-Barr virus latent membrane protein 1 (LMP1) and alters the LMP1/TRAF1/TRADD complex. Virology 1999; 264: 159-66.
30. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-52.
31. He Z, Xin B, Yang X, Chan C, Cao L. Nuclear factor-kappaB activation is involved in LMP1-mediated transformation and tumorigenesis of rat-1 fibroblasts. Cancer Res 2000; 60: 1845-8.
32. Eliopoulos AG, Young LS. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus encoded latent membrane protein 1 (LMP1). Oncogene 1998; 16: 1731-42.
33. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 1999; 274: 16085-96.
34. Vockerodt M, Haier B, Buttgereit P, Tesch H, Kube D. The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway. Virology 2001; 280: 183-98.
35. Shirakata M, Imadone KI, Okazaki K, Hirai K. Activation of TRAF5 and TRAF6 signal cascades negatively regulates the latent replication origin of Epstein-Barr virus through p38 mitogen-activated protein kinase. J Virol 2001; 75: 5059-68.
36. Schultheiss U, Puschner S, Kremmer E, et al. TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. Embo J 2001; 20: 5678-91.
37. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000; 95: 19-29.
38. Brennan P, Floettmann JE, Mehl A, Jones M, Rowe M. Mechanism of action of a novel latent membrane protein-1 dominant negative. J Biol Chem 2001; 276: 1195-203.
39. Izumi KM, Cahir-McFarland ED, Riley EA, Rizzo D, Chen Y, Kieff E. The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation. J Virol 1999; 73: 9908-16.
40. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci USA 2000; 97: 6055-60.
41. Asso-Bonnet M, Feuillard J, Ferreira V, et al. Relationship between IkappaBalpha constitutive expression, TNFalpha synthesis, and apoptosis in EBV-infected lymphoblastoid cells. Oncogene 1998; 17: 1607-15.
42. Feuillard J, Schuhmacher M, Kohanna S, et al. Inducible loss of NF-kappaB activity is associated with apoptosis and Bcl-2 down-regulation in Epstein-Barr virus-transformed B lymphocytes. Blood 2000; 95: 2068-75.
43. Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Scheidereit C. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001; 97: 2798-807.
44. Staudt LM. The molecular and cellular origins of Hodgkin's disease. J Exp Med 2000; 191: 207-12.
45. Knecht H, Berger C, McQuain C, et al. Latent membrane protein 1 associated signaling pathways are important in tumor cells of Epstein-Barr virus negative Hodgkin's disease. Oncogene 1999; 18: 7161-7.
46. Chen H, Lee JM, Zong Y, Borowitz M, Ng MH, Ambinder RF, Hayward SD. Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. J Virol 2001; 75: 2929-37.
47. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000; 19: 2489-95.
48. Lu JJ, Chen JY, Hsu TY, Yu WC, Su IJ, Yang CS. Induction of apoptosis in epithelial cells by Epstein-Barr virus latent membrane protein 1. J Gen Virol 1996; 77: 1883-92.
49. Liu Y, Wang X, Lo AK, Wong YC, Cheung AL, Tsao SW. Latent membrane protein-1 of Epstein-Barr virus inhibits cell growth and induces sensitivity to cisplatin in nasopharyngeal carcinoma cells. J Med Virol 2002; 66: 63-9.
50. Green DR, Evan GI. A matter of life and death. Cancer Cell 2002; 1: 19-30.